TY - JOUR
T1 - Unexpected Mutations by CRISPR-Cas9 CTG Repeat Excision in Myotonic Dystrophy and Use of CRISPR Interference as an Alternative Approach
AU - Ikeda, Miki
AU - Taniguchi-Ikeda, Mariko
AU - Kato, Takema
AU - Shinkai, Yasuko
AU - Tanaka, Sonoko
AU - Hagiwara, Hiroki
AU - Sasaki, Naomichi
AU - Masaki, Toshihiro
AU - Matsumura, Kiichiro
AU - Sonoo, Masahiro
AU - Kurahashi, Hiroki
AU - Saito, Fumiaki
N1 - Publisher Copyright:
© 2020 The Author(s)
PY - 2020/9/11
Y1 - 2020/9/11
N2 - Myotonic dystrophy type 1 is the most common type of adult-onset muscular dystrophy. This is an autosomal dominant disorder and caused by the expansion of the CTG repeat in the 3′ untranslated region of the dystrophia myotonica protein kinase (DMPK) gene. Messenger RNAs containing these expanded repeats form aggregates as nuclear RNA foci. Then, RNA binding proteins, including muscleblind-like 1, are sequestered to the RNA foci, leading to systemic abnormal RNA splicing. In this study, we used CRISPR-Cas9 genome editing to excise this CTG repeat. Dual cleavage at the 5′ and 3′ regions of the repeat using a conventional Cas9 nuclease and a double nicking with Cas9 nickase successfully excised the CTG repeat. Subsequently, the formation of the RNA foci was markedly reduced in patient-derived fibroblasts. However, contrary to expectations, a considerable amount of off-target digestions and on-target genomic rearrangements were observed using high-throughput genome-wide translocation sequencing. Finally, the suppression of DMPK transcripts using CRISPR interference significantly decreased the intensity of RNA foci. Our results indicate that close attention should be paid to the unintended mutations when double-strand breaks are generated by CRISPR-Cas9 for therapeutic purposes. Alternative approaches independent of double-strand breaks, including CRISPR interference, may be considered. Ikeda et al. report unexpected mutations caused by excision of the CTG repeat in the myotonic dystrophy locus using CRISPR-Cas9 and double nicking strategy. They further show that CRISPR interference significantly suppresses the RNA foci, proposing that the alternative approach independent of double-strand breaks may be considered for therapeutic purposes.
AB - Myotonic dystrophy type 1 is the most common type of adult-onset muscular dystrophy. This is an autosomal dominant disorder and caused by the expansion of the CTG repeat in the 3′ untranslated region of the dystrophia myotonica protein kinase (DMPK) gene. Messenger RNAs containing these expanded repeats form aggregates as nuclear RNA foci. Then, RNA binding proteins, including muscleblind-like 1, are sequestered to the RNA foci, leading to systemic abnormal RNA splicing. In this study, we used CRISPR-Cas9 genome editing to excise this CTG repeat. Dual cleavage at the 5′ and 3′ regions of the repeat using a conventional Cas9 nuclease and a double nicking with Cas9 nickase successfully excised the CTG repeat. Subsequently, the formation of the RNA foci was markedly reduced in patient-derived fibroblasts. However, contrary to expectations, a considerable amount of off-target digestions and on-target genomic rearrangements were observed using high-throughput genome-wide translocation sequencing. Finally, the suppression of DMPK transcripts using CRISPR interference significantly decreased the intensity of RNA foci. Our results indicate that close attention should be paid to the unintended mutations when double-strand breaks are generated by CRISPR-Cas9 for therapeutic purposes. Alternative approaches independent of double-strand breaks, including CRISPR interference, may be considered. Ikeda et al. report unexpected mutations caused by excision of the CTG repeat in the myotonic dystrophy locus using CRISPR-Cas9 and double nicking strategy. They further show that CRISPR interference significantly suppresses the RNA foci, proposing that the alternative approach independent of double-strand breaks may be considered for therapeutic purposes.
UR - https://www.scopus.com/pages/publications/85086739660
UR - https://www.scopus.com/pages/publications/85086739660#tab=citedBy
U2 - 10.1016/j.omtm.2020.05.024
DO - 10.1016/j.omtm.2020.05.024
M3 - Article
AN - SCOPUS:85086739660
SN - 2329-0501
VL - 18
SP - 131
EP - 144
JO - Molecular Therapy Methods and Clinical Development
JF - Molecular Therapy Methods and Clinical Development
ER -